Table 1.
Patient Characteristics
| Lorvotuzumab Mertansine Dose Level (mg/m2), n (%) | |||||||
|---|---|---|---|---|---|---|---|
| Characteristic | 40 (N = 3) |
60 (N = 3) |
75 (N = 3) |
90 (N = 3) |
112 (N = 19) |
140 (N = 6) |
Overall (N = 37) |
| Gender | |||||||
| Male | 2 (66.7) | 0 | 1 (33.3) | 2 (66.7) | 13 (68.4) | 3 (50) | 21 (56.8) |
| Female | 1 (33.3) | 3 (100) | 2 (66.7) | 1 (33.3) | 6 (31.6) | 3 (50) | 16 (43.2) |
| Age, y | |||||||
| Median | 66 | 69 | 55 | 58 | 61 | 64 | 61 |
| Range | 61–67 | 61–71 | 49–60 | 57–69 | 39–85 | 44–82 | 39–85 |
| Race | |||||||
| Caucasian | 1 (33.3) | 3 (100) | 2 (66.7) | 3 (100) | 19 (100) | 6 (100) | 34 (91.9) |
| African American | 1 (33.3) | 0 | 1 (33.3) | 0 | 0 | 0 | 2 (5.4) |
| Other | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 1 (2.7) |
| Median time since initial diagnosis, mos | 86.2 | 46.2 | 47 | 69.3 | 63.6 | 56.0 | 63.4 |
| ISS stage at diagnosis | |||||||
| I | 1 (33.3) | 0 | 0 | 0 | 5 (26.3) | 0 | 6 (16.2) |
| II | 0 | 0 | 0 | 0 | 4 (21.1) | 1 (16.7) | 5 (13.5) |
| III | 2 (66.6) | 3 (100) | 3 (100) | 3 (100) | 10 (52.6) | 5 (83.3) | 26 (70.3) |
| Disease status at study enrollment | |||||||
| Relapsed | 1 (33.3) | 1 (33.3) | 0 | 0 | 10 (52.6) | 4 (66.7) | 16 (43.2) |
| Relapsed and refractory | 2 (66.7) | 2 (66.7) | 3 (100) | 3 (100) | 9 (47.4) | 2 (33.3) | 21 (56.8) |
| Number of prior lines of therapy | |||||||
| 2 | 0 | 0 | 0 | 0 | 1 (5.3) | 1 (16.7) | 2 (5.4) |
| 3 | 0 | 0 | 0 | 0 | 5 (26.3) | 1 (16.7) | 6 (16.2) |
| >3 | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 13 (68.4) | 4 (66.7) | 29 (78.4) |
| Prior radiation therapy | 0 | 3 (100) | 2 (66.7) | 2 (66.7) | 8 (42.1) | 2 (33.3) | 17 (45.9) |
Abbreviation: ISS = International Staging System.